Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Alexandre A. B. A. da Costa"'
Autor:
Alexandre A. B. A. da Costa, Luisa M. do Canto, Simon Jonas Larsen, Adriana Regina Gonçalves Ribeiro, Carlos Eduardo Stecca, Annabeth Høgh Petersen, Mads M. Aagaard, Louise de Brot, Jan Baumbach, Glauco Baiocchi, Maria Isabel Achatz, Silvia Regina Rogatto
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Ovarian carcinomas presenting homologous recombination deficiency (HRD), which is observed in about 50% of cases, are more sensitive to platinum and PARP inhibitor therapies. Although platinum resistant disease has a low chance to
Externí odkaz:
https://doaj.org/article/91fc19a07d054507a624f51c215872e0
Autor:
Deborah Porto Cotrim, Adriana Regina Gonçalves Ribeiro, Daniele Paixão, Diogo Cordeiro de Queiroz Soares, Rima Jbili, Natasha Carvalho Pandolfi, Camila Cezana, Carine de Cássia Mauro, Henrique Mantoan, Graziele Bovolim, Louise de Brot, Giovana Tardin Torrezan, Dirce Maria Carraro, Glauco Baiocchi, Maria Nirvana da Cruz Formiga, Alexandre A. B. A. da Costa
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background BRCA1/2 pathogenic (P) and likely pathogenic (LP) germline variants are frequent among patients with ovarian carcinoma. However, these variants have not been extensively characterized in patients with ovarian cancer in Brazil. Met
Externí odkaz:
https://doaj.org/article/758ddea6326842a886213167f86a277b
Autor:
Panagiotis A. Konstantinopoulos, Alexandre André B. A. da Costa, Doga Gulhan, Elizabeth K. Lee, Su-Chun Cheng, Andrea E. Wahner Hendrickson, Bose Kochupurakkal, David L. Kolin, Elise C. Kohn, Joyce F. Liu, Elizabeth H. Stover, Jennifer Curtis, Nabihah Tayob, Madeline Polak, Dipanjan Chowdhury, Ursula A. Matulonis, Anniina Färkkilä, Alan D. D’Andrea, Geoffrey I. Shapiro
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-8 (2021)
A randomized phase 2 study recently showed that the addition of ATR inhibitor berzosertib to gemcitabine improved PFS compared to gemcitabine alone in patients with ovarian cancer. In this preplanned exploratory study, the authors demonstrate that a
Externí odkaz:
https://doaj.org/article/47ca4fa1fe9849e2a78a9dcd5d68a796
Autor:
Alexandre André B. A. da Costa, Dipanjan Chowdhury, Geoffrey I. Shapiro, Alan D. D’Andrea, Panagiotis A. Konstantinopoulos
Publikováno v:
Nature Reviews Drug Discovery. 22:38-58
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90f54f684fb082f1fe82fba88bc82d4a
https://doi.org/10.1038/s41573-022-00558-5
https://doi.org/10.1038/s41573-022-00558-5
Autor:
Alexandre Andre B. A. Da Costa, Arindam Bose, David Martignetti, Cecilia Ayala-Zambrano, Ramya Ravindranathan, Golbahar Sadatrezaei, Yuqing Jiao, Bose Kochupurakkal, Huy Nguyen, Jean-Bernard Lazaro, Kalindi Parmar, Geoffrey I. Shapiro, Alan D. D’Andrea
Publikováno v:
Cancer Research. 83:5725-5725
Targeting BRCA-deficient tumors with PARP inhibitors has improved the progression-free survival of ovarian and breast cancer patients in the clinic. However, the majority of patients develop acquired resistance. PARP inhibitor (PARPi) resistance in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b58785e205032faaa1befe9aea3e3c8
https://doi.org/10.1158/1538-7445.am2023-5725
https://doi.org/10.1158/1538-7445.am2023-5725